Aspergillosis Cell Models for Research

Aspergillosis is a fungal infection caused by Aspergillus species, primarily A. fumigatus. Invasive aspergillosis (IA) is a major cause of morbidity and mortality in immunocompromised patients, with an estimated global incidence of over 300,000 cases annually (WHO). The overall mortality rate for IA ranges from 30% to 95% depending on the patient population and timely diagnosis (NCI). Chronic pulmonary aspergillosis (CPA) affects an estimated 3 million people worldwide, with a 5-year survival rate of approximately 50% (NCI). Allergic bronchopulmonary aspergillosis (ABPA) complicates asthma and cystic fibrosis, affecting millions more. Key risk factors include prolonged neutropenia, hematopoietic stem cell or solid organ transplantation, hematological malignancies, and immunosuppressive therapies. The rising use of biologics and immunomodulators has expanded the at-risk population, underscoring the need for better therapeutic strategies and research models.

Aspergillosis is an ideal model for studying host-pathogen interactions, innate immunity, and fungal virulence. The disease presents distinct clinical forms (invasive, chronic, allergic) that reflect different host immune states, providing a spectrum for mechanistic studies. Public datasets, such as those from the NCBI Gene Expression Omnibus (GEO), contain transcriptomic profiles of infected human and mouse tissues, enabling systems-level analyses. Open questions include the molecular basis of immune evasion, the role of specific pattern recognition receptors (e.g., Dectin-1, TLRs), and the development of resistance to antifungal drugs. Gene-edited cell models are essential to dissect these pathways and validate therapeutic targets.

Aspergillus infection triggers several host signaling pathways that determine the outcome of infection. Key pathways include:

• • Dectin-1/Syk/CARD9 pathway: Recognizes β-glucan on fungal cell walls, leading to NF-κB activation and pro-inflammatory cytokine production.
• • TLR2/TLR4/MyD88 pathway: Recognizes fungal components, activating innate immune responses.
• • Inflammasome pathway: Activation of NLRP3 by fungal toxins (e.g., gliotoxin) leads to IL-1β and IL-18 secretion.
• • PI3K/AKT/mTOR pathway: Modulates phagocytosis and autophagy, affecting fungal clearance.
• • Apoptosis pathway: Fungal metabolites can induce host cell apoptosis, facilitating immune evasion.

These pathways are interconnected, and their dysregulation can lead to either uncontrolled infection or excessive inflammation.

While the host genome does not typically harbor mutations causing aspergillosis, genetic polymorphisms in immune genes influence susceptibility. The following table summarizes key variants associated with increased risk (data from ClinVar and literature).

These variants are not somatic mutations but germline polymorphisms that can be modeled in cell lines to study their functional impact.

During aspergillosis, the host immune signaling networks are either suppressed or overactivated, depending on the stage. Key nodes include:

• • Pattern recognition receptors (PRRs): Dectin-1, TLR2, TLR4, and DC-SIGN.
• • Adapter molecules: Syk, MyD88, TRIF, CARD9.
• • Transcription factors: NF-κB, AP-1, IRF3, and STAT3.
• • Cytokines: TNF-α, IL-6, IL-1β, IL-12, and IFN-γ.
• • Inflammasome components: NLRP3, ASC, Caspase-1.

Aspergillus also secretes toxins (e.g., gliotoxin) that inhibit NF-κB and induce apoptosis, thereby suppressing host defenses. Understanding these networks is crucial for identifying drug targets.

Commonly used cell lines for aspergillosis research include:

Organoids derived from lung or gut epithelium are emerging as more physiologically relevant models, allowing study of fungal invasion in 3D architecture and cell-cell interactions.

Animal models are essential for studying aspergillosis in vivo. Common models include:

• • Immunosuppressed mouse models: Mice treated with cyclophosphamide or corticosteroids to induce neutropenia, then infected intranasally or intravenously with A. fumigatus conidia.
• • Genetically engineered mouse models (GEMMs): Mice with targeted deletions in immune genes (e.g., Dectin-1 knockout, CARD9 knockout) to study susceptibility.
• • Patient-derived xenografts (PDX): Not commonly used for fungal infections, but humanized mice engrafted with human immune cells can model human-specific responses.
• • Non-mammalian models: Drosophila and Galleria mellonella are used for high-throughput screening of virulence and antifungal compounds.

CRISPR-based gene editing has enabled the creation of isogenic cell lines with precise genetic modifications to study host factors in aspergillosis. For example:

• • Dectin-1 knockout A549 cells: Used to assess the role of Dectin-1 in fungal recognition and cytokine production.
• • TLR4 knockout THP-1 cells: Help dissect TLR4-mediated signaling in response to Aspergillus.
• • CARD9 knockout macrophages: Elucidate the CARD9-dependent pathway in antifungal immunity.
• • Reporter cell lines: e.g., NF-κB reporter lines to monitor pathway activation upon fungal exposure.

These gene-edited models are commercially available from various sources, ensuring sequence verification and quality. They accelerate research by providing consistent, controlled genetic backgrounds, reducing experimental variability.

Gene-edited cell lines are invaluable for functional genomics studies. For example:

• • Knockout of Dectin-1 in macrophages reduces cytokine production and fungal killing, confirming its role in host defense.
• • Knock-in of a CARD9 mutation (e.g., S12N) can increase susceptibility to infection, modeling human genetic risk.
• • CRISPR screens using pooled libraries can identify novel host factors required for Aspergillus uptake or killing.

These models allow researchers to validate candidate genes from GWAS and transcriptomic studies.

Isogenic cell line pairs (wild-type vs. gene-edited) are powerful tools for drug screening. For instance:

• • Screening antifungal compounds in Dectin-1 knockout cells can reveal whether efficacy depends on host immune function.
• • Resistance to azoles can be modeled by introducing mutations in the fungal Cyp51A gene, but host cell models can also be used to study efflux pump expression.
• • Combination therapies (antifungal + immunomodulator) can be tested in gene-edited immune cells to assess synergistic effects.

These approaches help identify drugs that enhance host immunity or overcome resistance.

CRISPR-based synthetic lethality screens can identify host genes that, when inhibited, sensitize cells to Aspergillus infection or enhance fungal killing. For example:

• • Knockout of specific kinases may increase the production of reactive oxygen species, improving fungal clearance.
• • Screening for genes that regulate inflammation can identify biomarkers for disease severity.

Gene-edited cell lines can also be used to validate biomarkers discovered in patient cohorts, such as cytokine profiles or surface markers.